Join Clinical Trials
  • Login
  • Home
  • Clinical Trial Categories
  • Youths - Birth - 17
  • Louisiana
  • New Orleans


Menu

Choose Which Database to Search - Volunteer Database - Clinical Trial Database Create an Account - VOLUNTEER Accounts - RECRUITER Accounts Account Login - Volunteers Login - Recruiters Login Join a Clinical Trial Clinical Trials by Category Clinical Trials by Location Submit a Clinical Trial Frequently Asked Questions Contact Us Sitemap Blog

Categories

    Healthy Volunteers Adults - 18 - 64 Youths - Birth - 17 Seniors - 65 + Expanded Access Compensated Trials Clinical Trials by Condition Trials by Drug Type Trials for Rare Conditions

Recent Listings

  • Post your clinical trial on JoinClinicalTrials.com

    Ellijay, Georgia 30536
    United States

    Post your clinical trial on JoinClinicalTrials.com

    05-09-2019 01:01PM

JoinClinicalTrials.com




Results

Post your clinical trial on JoinClinicalTrials.com
Hot

Post your clinical trial on JoinClinicalTrials.com


Ellijay, Georgia 30536
United States

Post your clinical trial on JoinClinicalTrials.com to reach thousands of viewer daily. Our Clinical Trial Listings have consistently proven to be an ...

Results 1 - 1 of 1
  • <<
  • <
  • 1
  • >
  • >>

  • Vertebral Body Tethering Treatment for Idiopathic Scoliosis
    NCT03802656
    Conditions:   Scoliosis;   Spinal Curvatures;   Spinal Diseases;   Bone Diseases;   Musculoskeletal Disease;   Adolescent Idiopathic Scoliosis;   Juvenile; Scoliosis
    Intervention:   Device: Anterior Vertebral Body Tethering
    Sponsor:   Lawrence Haber
    Recruiting
  • Engaging Seronegative Youth to Optimize HIV Prevention Continuum
    NCT03134833
    Conditions:   HIV;   Mental Health;   Substance Use;   STI
    Interventions:   Behavioral: Automated Messaging & Monitoring;   Behavioral: Peer Support;   Behavioral: Coaching
    Sponsors:   University of California, Los Angeles;   Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD);   Tulane University Health Sciences Center;   University of California, San Francisco;   Friends Research Institute, Inc.
    Recruiting
  • Stepped Care for Youth Living With HIV
    NCT03109431
    Conditions:   HIV;   Mental Health;   Illicit Substance Use;   Sexually Transmitted Infections (STI)
    Interventions:   Behavioral: Level 1;   Behavioral: Level 2;   Behavioral: Level 3
    Sponsors:   University of California, Los Angeles;   Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD);   Wake Forest University Health Sciences;   Tulane University Health Sciences Center;   Columbia University
    Recruiting
  • Prevention and Treatment Continuum for Youth at HIV Risk, Acutely Infected and With Established HIV Infection
    NCT03205696
    Condition:   Human Immunodeficiency Virus
    Intervention:   Drug: Antiretrovirals
    Sponsors:   University of California, Los Angeles;   Los Angeles LGBT Center;   Tulane University
    Recruiting
  • Treatment Efforts Addressing Child Weight Management by Unifying Patients, Parents & Providers
    NCT03843424
    Condition:   Obesity, Childhood
    Interventions:   Behavioral: eSOC program;   Behavioral: FBT program
    Sponsors:   Washington University School of Medicine;   Patient-Centered Outcomes Research Institute;   Blue Cross Blue Shield of Louisiana;   Louisiana Healthcare Connections;   American Academy of Pediatrics;   Pennington Biomedical Research Center;   University of Rochester
    Recruiting
  • Short-course Benznidazole Treatment to Reduce Trypanosoma Cruzi Parasitic Load in Women of Reproductive Age
    NCT03672487
    Condition:   Chagas Disease
    Interventions:   Drug: Benznidazole;   Drug: Placebo Oral Tablet
    Sponsors:   Tulane University School of Public Health and Tropical Medicine;   Institute for Clinical Effectiveness and Health Policy;   University of California, San Diego
    Recruiting
  • iKanEat: A Randomized-controlled, Multi-center Trial of Megestrol for Chronic Oral Food Refusal in Children
    NCT03815019
    Conditions:   Feeding Behavior;   Feeding Disorder of Infancy or Early Childhood
    Interventions:   Drug: Megestrol Acetate;   Behavioral: iKanEat Behavioral Intervention
    Sponsor:   University of Kansas Medical Center
    Recruiting
  • Effects of Emicizumab vs. Factor VIII Prophylaxis on Joint and Bone Health in Severe Hemophilia A
    NCT04131036
    Condition:   Hemophilia A
    Intervention:   Other: assessment of joint health and bone density
    Sponsors:   Bloodworks;   Genentech, Inc.
    Recruiting
  • Azacitidine and Combination Chemotherapy in Treating Infants With Acute Lymphoblastic Leukemia and KMT2A Gene Rearrangement
    NCT02828358
    Conditions:   Acute Leukemia of Ambiguous Lineage;   B Acute Lymphoblastic Leukemia;   Mixed Phenotype Acute Leukemia
    Interventions:   Drug: Azacitidine;   Drug: Cyclophosphamide;   Drug: Cytarabine;   Drug: Daunorubicin;   Drug: Daunorubicin Hydrochloride;   Drug: Dexamethasone;   Drug: Hydrocortisone Sodium Succinate;   Other: Laboratory Biomarker Analysis;   Drug: Leucovorin;   Drug: Leucovorin Calcium;   Drug: Mercaptopurine;   Drug: Methotrexate;   Drug: Pegaspargase;   Other: Pharmacological Study;   Drug: Prednisolone;   Drug: Thioguanine;   Drug: Vincristine;   Drug: Vincristine Sulfate
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • A Study of the Safety and Effectiveness of Apixaban in Preventing Blood Clots in Children With Leukemia Who Have a Central Venous Catheter and Are Treated With Asparaginase
    NCT02369653
    Conditions:   Lymphoma;   Acute Lymphoblastic Leukemia
    Interventions:   Drug: Apixaban;   Other: No systemic anticoagulant prophylaxis
    Sponsors:   Bristol-Myers Squibb;   Pfizer
    Recruiting
  • Response and Biology-Based Risk Factor-Guided Therapy in Treating Younger Patients With Non-high Risk Neuroblastoma
    NCT02176967
    Conditions:   Ganglioneuroblastoma;   Localized Resectable Neuroblastoma;   Localized Unresectable Neuroblastoma;   Neuroblastoma
    Interventions:   Drug: Carboplatin;   Other: Clinical Observation;   Drug: Cyclophosphamide;   Drug: Doxorubicin Hydrochloride;   Drug: Etoposide;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting
  • Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
    NCT03959085
    Conditions:   B Acute Lymphoblastic Leukemia;   B Lymphoblastic Lymphoma;   Central Nervous System Leukemia;   Mixed Phenotype Acute Leukemia;   Testicular Leukemia
    Interventions:   Drug: Cyclophosphamide;   Drug: Cytarabine;   Drug: Daunorubicin;   Drug: Daunorubicin Hydrochloride;   Drug: Dexamethasone;   Drug: Doxorubicin;   Drug: Doxorubicin Hydrochloride;   Biological: Inotuzumab Ozogamicin;   Drug: Leucovorin;   Drug: Leucovorin Calcium;   Drug: Mercaptopurine;   Drug: Methotrexate;   Drug: Pegaspargase;   Drug: Prednisolone;   Other: Questionnaire Administration;   Radiation: Radiation Therapy;   Drug: Thioguanine;   Drug: Vincristine;   Drug: Vincristine Sulfate
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting
  • A Study to Determine the Outcomes of Patients With Localized B Cell Lymphoblastic Lymphoma (B-LLy) When Treated With Standard Risk B-ALL Therapy
    NCT03914625
    Conditions:   B Acute Lymphoblastic Leukemia;   B Lymphoblastic Lymphoma;   Down Syndrome
    Interventions:   Drug: Asparaginase Erwinia chrysanthemi;   Biological: Blinatumomab;   Drug: Cyclophosphamide;   Drug: Cytarabine;   Drug: Dexamethasone;   Drug: Doxorubicin;   Drug: Doxorubicin Hydrochloride;   Drug: Leucovorin;   Drug: Leucovorin Calcium;   Drug: Mercaptopurine;   Drug: Mercaptopurine Oral Suspension;   Drug: Methotrexate;   Drug: Prednisolone;   Drug: Prednisone;   Drug: Thioguanine;   Drug: Vincristine;   Drug: Vincristine Sulfate
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery
    NCT03533582
    Conditions:   Childhood Hepatocellular Carcinoma;   Childhood Malignant Liver Neoplasm;   Hepatoblastoma;   Hepatocellular Malignant Neoplasm, Not Otherwise Specified;   SMARCB1 Gene Mutation
    Interventions:   Drug: Carboplatin;   Drug: Cisplatin;   Drug: Doxorubicin;   Drug: Etoposide;   Drug: Fluorouracil;   Drug: Gemcitabine;   Drug: Irinotecan;   Other: Laboratory Biomarker Analysis;   Drug: Oxaliplatin;   Other: Patient Observation;   Drug: Sorafenib;   Drug: Vincristine Sulfate
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting
  • Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial)
    NCT03526250
    Conditions:   Advanced Malignant Solid Neoplasm;   Recurrent Childhood Ependymoma;   Recurrent Ewing Sarcoma;   Recurrent Glioma;   Recurrent Hepatoblastoma;   Recurrent Kidney Wilms Tumor;   Recurrent Langerhans Cell Histiocytosis;   Recurrent Malignant Germ Cell Tumor;   Recurrent Malignant Glioma;   Recurrent Medulloblastoma;   Recurrent Neuroblastoma;   Recurrent Non-Hodgkin Lymphoma;   Recurrent Osteosarcoma;   Recurrent Peripheral Primitive Neuroectodermal Tumor;   Recurrent Rhabdoid Tumor;   Recurrent Rhabdomyosarcoma;   Recurrent Soft Tissue Sarcoma;   Refractory Ependymoma;   Refractory Ewing Sarcoma;   Refractory Glioma;   Refractory Hepatoblastoma;   Refractory Langerhans Cell Histiocytosis;   Refractory Malignant Germ Cell Tumor;   Refractory Malignant Glioma;   Refractory Medulloblastoma;   Refractory Neuroblastoma;   Refractory Non-Hodgkin Lymphoma;   Refractory Osteosarcoma;   Refractory Peripheral Primitive Neuroectodermal Tumor;   Refractory Rhabdoid Tumor;   Refractory Rhabdomyosarcoma;   Refractory Soft Tissue Sarcoma
    Interventions:   Other: Laboratory Biomarker Analysis;   Drug: Palbociclib;   Other: Pharmacological Study
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial)
    NCT03233204
    Conditions:   Advanced Malignant Solid Neoplasm;   Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma;   Ann Arbor Stage IV Childhood Non-Hodgkin Lymphoma;   Low Grade Glioma;   Malignant Glioma;   Recurrent Childhood Central Nervous System Neoplasm;   Recurrent Childhood Ependymoma;   Recurrent Childhood Malignant Germ Cell Tumor;   Recurrent Childhood Non-Hodgkin Lymphoma;   Recurrent Childhood Rhabdomyosarcoma;   Recurrent Childhood Soft Tissue Sarcoma;   Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor;   Recurrent Glioma;   Recurrent Hepatoblastoma;   Recurrent Langerhans Cell Histiocytosis;   Recurrent Malignant Solid Neoplasm;   Recurrent Medulloblastoma;   Recurrent Neuroblastoma;   Recurrent Osteosarcoma;   Refractory Central Nervous System Neoplasm;   Refractory Childhood Malignant Germ Cell Tumor;   Refractory Ependymoma;   Refractory Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor;   Refractory Glioma;   Refractory Hepatoblastoma;   Refractory Langerhans Cell Histiocytosis;   Refractory Malignant Glioma;   Refractory Malignant Solid Neoplasm;   Refractory Medulloblastoma;   Refractory Neuroblastoma;   Refractory Non-Hodgkin Lymphoma;   Refractory Osteosarcoma;   Refractory Rhabdomyosarcoma;   Refractory Soft Tissue Sarcoma;   Rhabdoid Tumor;   Wilms Tumor
    Intervention:   Drug: Olaparib
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial)
    NCT03220035
    Conditions:   Advanced Malignant Solid Neoplasm;   Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma;   Ann Arbor Stage IV Childhood Non-Hodgkin Lymphoma;   Ependymoma;   Ewing Sarcoma;   Hepatoblastoma;   Langerhans Cell Histiocytosis;   Malignant Germ Cell Tumor;   Malignant Glioma;   Osteosarcoma;   Peripheral Primitive Neuroectodermal Tumor;   Recurrent Childhood Central Nervous System Neoplasm;   Recurrent Childhood Non-Hodgkin Lymphoma;   Recurrent Malignant Solid Neoplasm;   Recurrent Neuroblastoma;   Refractory Central Nervous System Neoplasm;   Refractory Malignant Solid Neoplasm;   Refractory Neuroblastoma;   Refractory Non-Hodgkin Lymphoma;   Rhabdoid Tumor;   Rhabdomyosarcoma;   Soft Tissue Sarcoma;   Wilms Tumor
    Interventions:   Other: Laboratory Biomarker Analysis;   Drug: Vemurafenib
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial)
    NCT03213704
    Conditions:   Advanced Malignant Solid Neoplasm;   Recurrent Ependymoma;   Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor;   Recurrent Glioma;   Recurrent Hepatoblastoma;   Recurrent Langerhans Cell Histiocytosis;   Recurrent Malignant Germ Cell Tumor;   Recurrent Malignant Glioma;   Recurrent Malignant Solid Neoplasm;   Recurrent Medulloblastoma;   Recurrent Neuroblastoma;   Recurrent Non-Hodgkin Lymphoma;   Recurrent Osteosarcoma;   Recurrent Rhabdoid Tumor;   Recurrent Rhabdomyosarcoma;   Recurrent Soft Tissue Sarcoma;   Refractory Central Nervous System Neoplasm;   Refractory Ependymoma;   Refractory Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor;   Refractory Glioma;   Refractory Hepatoblastoma;   Refractory Langerhans Cell Histiocytosis;   Refractory Malignant Germ Cell Tumor;   Refractory Malignant Glioma;   Refractory Malignant Solid Neoplasm;   Refractory Neuroblastoma;   Refractory Non-Hodgkin Lymphoma;   Refractory Osteosarcoma;   Refractory Rhabdoid Tumor;   Refractory Rhabdomyosarcoma;   Wilms Tumor
    Interventions:   Drug: Larotrectinib;   Drug: Larotrectinib Sulfate
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • PI3K/mTOR Inhibitor LY3023414 in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial)
    NCT03213678
    Conditions:   Advanced Malignant Solid Neoplasm;   Ann Arbor Stage III Non-Hodgkin Lymphoma;   Ann Arbor Stage IV Non-Hodgkin Lymphoma;   Malignant Glioma;   Recurrent Central Nervous System Neoplasm;   Recurrent Ependymoma;   Recurrent Ewing Sarcoma;   Recurrent Glioma;   Recurrent Hepatoblastoma;   Recurrent Langerhans Cell Histiocytosis;   Recurrent Malignant Germ Cell Tumor;   Recurrent Malignant Solid Neoplasm;   Recurrent Medulloblastoma;   Recurrent Neuroblastoma;   Recurrent Non-Hodgkin Lymphoma;   Recurrent Osteosarcoma;   Recurrent Peripheral Primitive Neuroectodermal Tumor;   Recurrent Rhabdomyosarcoma;   Recurrent Soft Tissue Sarcoma;   Refractory Central Nervous System Neoplasm;   Refractory Langerhans Cell Histiocytosis;   Refractory Malignant Germ Cell Tumor;   Refractory Malignant Solid Neoplasm;   Refractory Neuroblastoma;   Refractory Non-Hodgkin Lymphoma;   Rhabdoid Tumor;   Stage III Osteosarcoma AJCC v7;   Stage III Soft Tissue Sarcoma AJCC v7;   Stage IV Osteosarcoma AJCC v7;   Stage IV Soft Tissue Sarcoma AJCC v7;   Stage IVA Osteosarcoma AJCC v7;   Stage IVB Osteosarcoma AJCC v7;   Wilms Tumor
    Interventions:   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study;   Drug: Samotolisib
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial)
    NCT03213665
    Conditions:   Advanced Malignant Solid Neoplasm;   Ann Arbor Stage III Hodgkin Lymphoma;   Ann Arbor Stage III Non-Hodgkin Lymphoma;   Ann Arbor Stage IV Hodgkin Lymphoma;   Ann Arbor Stage IV Non-Hodgkin Lymphoma;   Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor;   EZH2 Gene Mutation;   Low Grade Glioma;   Recurrent Central Nervous System Neoplasm;   Recurrent Ependymoma;   Recurrent Ewing Sarcoma;   Recurrent Glioma;   Recurrent Hepatoblastoma;   Recurrent Hodgkin Lymphoma;   Recurrent Langerhans Cell Histiocytosis;   Recurrent Malignant Germ Cell Tumor;   Recurrent Malignant Glioma;   Recurrent Malignant Solid Neoplasm;   Recurrent Medulloblastoma;   Recurrent Neuroblastoma;   Recurrent Non-Hodgkin Lymphoma;   Recurrent Osteosarcoma;   Recurrent Peripheral Primitive Neuroectodermal Tumor;   Recurrent Rhabdoid Tumor;   Recurrent Rhabdomyosarcoma;   Recurrent Soft Tissue Sarcoma;   Refractory Hodgkin Lymphoma;   Refractory Langerhans Cell Histiocytosis;   Refractory Malignant Germ Cell Tumor;   Refractory Malignant Glioma;   Refractory Malignant Solid Neoplasm;   Refractory Medulloblastoma;   Refractory Neuroblastoma;   Refractory Non-Hodgkin Lymphoma;   Refractory Osteosarcoma;   Refractory Peripheral Primitive Neuroectodermal Tumor;   Refractory Rhabdoid Tumor;   Refractory Soft Tissue Sarcoma;   Rhabdoid Tumor;   SMARCA4 Gene Inactivation;   SMARCB1 Gene Inactivation;   Stage III Soft Tissue Sarcoma AJCC v7;   Stage IV Soft Tissue Sarcoma AJCC v7;   Wilms Tumor
    Interventions:   Other: Laboratory Biomarker Analysis;   Drug: Tazemetostat
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial)
    NCT03213652
    Conditions:   Advanced Malignant Solid Neoplasm;   ALK Fusion Protein Expression;   ALK Gene Mutation;   Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma;   Ann Arbor Stage IV Childhood Non-Hodgkin Lymphoma;   Recurrent Childhood Central Nervous System Neoplasm;   Recurrent Childhood Non-Hodgkin Lymphoma;   Recurrent Malignant Solid Neoplasm;   Recurrent Neuroblastoma;   Refractory Central Nervous System Neoplasm;   Refractory Malignant Solid Neoplasm;   Refractory Neuroblastoma;   Refractory Non-Hodgkin Lymphoma;   ROS1 Fusion Positive;   ROS1 Gene Mutation
    Interventions:   Drug: Ensartinib;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)
    NCT03210714
    Conditions:   Advanced Malignant Solid Neoplasm;   Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma;   Ann Arbor Stage IV Childhood Non-Hodgkin Lymphoma;   Low Grade Glioma;   Malignant Glioma;   Recurrent Central Nervous System Neoplasm;   Recurrent Childhood Ependymoma;   Recurrent Childhood Malignant Germ Cell Tumor;   Recurrent Childhood Medulloblastoma;   Recurrent Childhood Non-Hodgkin Lymphoma;   Recurrent Childhood Rhabdomyosarcoma;   Recurrent Childhood Soft Tissue Sarcoma;   Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor;   Recurrent Hepatoblastoma;   Recurrent Langerhans Cell Histiocytosis;   Recurrent Malignant Solid Neoplasm;   Recurrent Neuroblastoma;   Recurrent Osteosarcoma;   Refractory Central Nervous System Neoplasm;   Refractory Langerhans Cell Histiocytosis;   Refractory Malignant Solid Neoplasm;   Refractory Neuroblastoma;   Refractory Non-Hodgkin Lymphoma;   Rhabdoid Tumor;   Stage III Soft Tissue Sarcoma AJCC v7;   Stage IV Soft Tissue Sarcoma AJCC v7;   Wilms Tumor
    Interventions:   Drug: Erdafitinib;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • Cancer Care Delivery in Adolescent and Young Adult Patients With Acute Lymphoblastic Leukemia
    NCT03204916
    Condition:   Acute Lymphoblastic Leukemia
    Interventions:   Other: Medical Chart Review;   Other: Questionnaire Administration
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting
  • Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)
    NCT03155620
    Conditions:   Advanced Malignant Solid Neoplasm;   Ann Arbor Stage III Non-Hodgkin Lymphoma;   Ann Arbor Stage IV Non-Hodgkin Lymphoma;   Histiocytic Sarcoma;   Juvenile Xanthogranuloma;   Langerhans Cell Histiocytosis;   Malignant Glioma;   Recurrent Central Nervous System Neoplasm;   Recurrent Childhood Rhabdomyosarcoma;   Recurrent Ependymoma;   Recurrent Ewing Sarcoma;   Recurrent Glioma;   Recurrent Hepatoblastoma;   Recurrent Langerhans Cell Histiocytosis;   Recurrent Malignant Germ Cell Tumor;   Recurrent Malignant Solid Neoplasm;   Recurrent Medulloblastoma;   Recurrent Neuroblastoma;   Recurrent Non-Hodgkin Lymphoma;   Recurrent Osteosarcoma;   Recurrent Peripheral Primitive Neuroectodermal Tumor;   Recurrent Rhabdoid Tumor;   Recurrent Soft Tissue Sarcoma;   Refractory Central Nervous System Neoplasm;   Refractory Ewing Sarcoma;   Refractory Glioma;   Refractory Hepatoblastoma;   Refractory Langerhans Cell Histiocytosis;   Refractory Malignant Germ Cell Tumor;   Refractory Malignant Solid Neoplasm;   Refractory Medulloblastoma;   Refractory Neuroblastoma;   Refractory Non-Hodgkin Lymphoma;   Refractory Osteosarcoma;   Refractory Peripheral Primitive Neuroectodermal Tumor;   Refractory Rhabdoid Tumor;   Refractory Rhabdomyosarcoma;   Rhabdoid Tumor;   Stage III Osteosarcoma AJCC v7;   Stage III Soft Tissue Sarcoma AJCC v7;   Stage IV Osteosarcoma AJCC v7;   Stage IV Soft Tissue Sarcoma AJCC v7;   Stage IVA Osteosarcoma AJCC v7;   Stage IVB Osteosarcoma AJCC v7;   Wilms Tumor
    Interventions:   Procedure: Biopsy;   Procedure: Biospecimen Collection;   Drug: Ensartinib;   Drug: Erdafitinib;   Other: Laboratory Biomarker Analysis;   Drug: Larotrectinib;   Procedure: Mutation Carrier Screening;   Drug: Olaparib;   Drug: Palbociclib;   Other: Pharmacological Study;   Drug: Samotolisib;   Drug: Selumetinib Sulfate;   Drug: Tazemetostat;   Drug: Ulixertinib;   Drug: Vemurafenib
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • Identifying, Understanding, and Overcoming Barriers to the Use of Clinical Practice Guidelines in Pediatric Oncology
    NCT02847130
    Conditions:   Acute Lymphoblastic Leukemia;   B-Cell Non-Hodgkin Lymphoma;   Chemotherapy-Related Nausea and/or Vomiting;   Childhood Acute Myeloid Leukemia;   Childhood Burkitt Lymphoma;   Childhood Neoplasm;   Febrile Neutropenia;   Hematopoietic Cell Transplant Recipient;   Recurrent Childhood Acute Lymphoblastic Leukemia;   Untreated Childhood Acute Lymphoblastic Leukemia
    Interventions:   Other: Informational Intervention;   Other: Interview;   Other: Medical Chart Review;   Other: Questionnaire Administration
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting
  • STRIDE Biorepository
    NCT02843347
    Condition:   Anemia, Sickle Cell
    Intervention:   Procedure: Blood draw
    Sponsors:   Emory University;   National Heart, Lung, and Blood Institute (NHLBI)
    Recruiting
  • Reduced Craniospinal Radiation Therapy and Chemotherapy in Treating Younger Patients With Newly Diagnosed WNT-Driven Medulloblastoma
    NCT02724579
    Conditions:   CTNNB1 Gene Mutation;   Medulloblastoma;   Wnt Positive
    Interventions:   Drug: Cisplatin;   Drug: Cyclophosphamide;   Other: Laboratory Biomarker Analysis;   Drug: Lomustine;   Radiation: Radiation Therapy;   Drug: Vincristine;   Drug: Vincristine Sulfate
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting
  • Combination Chemotherapy With or Without Temsirolimus in Treating Patients With Intermediate Risk Rhabdomyosarcoma
    NCT02567435
    Conditions:   Alveolar Rhabdomyosarcoma;   Botryoid-Type Embryonal Rhabdomyosarcoma;   Embryonal Rhabdomyosarcoma;   Rhabdomyosarcoma;   Sclerosing Rhabdomyosarcoma;   Spindle Cell Rhabdomyosarcoma
    Interventions:   Drug: Cyclophosphamide;   Biological: Dactinomycin;   Drug: Irinotecan Hydrochloride;   Other: Laboratory Biomarker Analysis;   Other: Questionnaire Administration;   Radiation: Radiation Therapy;   Drug: Temsirolimus;   Drug: Vincristine Sulfate;   Drug: Vinorelbine
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • Safety, PK and Effectiveness of IV Peramivir Versus Oseltamivir in Pediatric Subjects With Uncomplicated Influenza
    NCT02369159
    Condition:   Influenza
    Interventions:   Drug: Peramivir;   Drug: Oseltamivir
    Sponsor:   BioCryst Pharmaceuticals
    Recruiting
  • A Clinical Efficacy and Safety Study of SHP607 in Preventing Chronic Lung Disease in Extremely Premature Infants
    NCT03253263
    Conditions:   Retinopathy of Prematurity (ROP);   Intraventricular Hemorrhage;   Bronchopulmonary Dysplasia;   Chronic Lung Disease of Prematurity
    Intervention:   Drug: SHP607
    Sponsor:   Shire
    Recruiting
  • A Study on Safety, Pharmacokinetics and Pharmacodynamics of Lixisenatide in Pediatric Patients With Type 2 Diabetes Mellitus (T2DM)
    NCT02803918
    Condition:   Type 2 Diabetes Mellitus
    Interventions:   Drug: Lixisenatide (AVE0010);   Drug: Placebo;   Drug: Basal Insulin;   Drug: Metformin
    Sponsor:   Sanofi
    Recruiting
  • A Study of MACI in Patients Aged 10 to 17 Years With Symptomatic Chondral or Osteochondral Defects of the Knee
    NCT03588975
    Conditions:   Chondral Defect;   Osteochondritis Dissecans;   Articular Cartilage Defect;   Articular Cartilage Disorder of Knee
    Interventions:   Biological: MACI;   Procedure: microfracture
    Sponsor:   Vericel Corporation
    Recruiting
  • Study Evaluating PK/PD and Safety of Betrixaban in Pediatric Patients
    NCT03346083
    Condition:   VTE Prophylaxis
    Intervention:   Drug: Betrixaban
    Sponsor:   Portola Pharmaceuticals
    Recruiting
  • Safety of Sildenafil in Premature Infants
    NCT03142568
    Condition:   Bronchopulmonary Dysplasia
    Interventions:   Drug: Sildenafil;   Other: Placebo
    Sponsors:   University of North Carolina, Chapel Hill;   Duke University;   Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD);   The Emmes Company, LLC
    Recruiting
  • Safety and Efficacy of Nerivio™ for the Acute Treatment of Migraine in Adolescents
    NCT04089761
    Condition:   Acute Migraine
    Intervention:   Device: Nerivio
    Sponsor:   Theranica
    Recruiting
  • OPN-375 Efficacy and Safety in Adolescents With Bilateral Nasal Polyps
    NCT03747458
    Condition:   Bilateral Nasal Polyposis
    Intervention:   Drug: OPN-375
    Sponsor:   Optinose US Inc.
    Recruiting
  • Diabetes Study of Linagliptin and Empagliflozin in Children and Adolescents (DINAMO)TM
    NCT03429543
    Condition:   Diabetes Mellitus, Type 2
    Interventions:   Drug: Linagliptin;   Drug: Empagliflozin;   Drug: Placebo
    Sponsor:   Boehringer Ingelheim
    Recruiting
  • Web-Based Physical Activity Intervention in Improving Long Term Health in Children and Adolescents With Newly Diagnosed Acute Lymphoblastic Leukemia in First Remission
    NCT03223753
    Condition:   Acute Lymphoblastic Leukemia in Remission
    Interventions:   Other: Educational Intervention;   Other: Internet-Based Intervention;   Other: Laboratory Biomarker Analysis;   Device: Monitoring Device;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting
  • Safety and Efficacy of Nonacog Beta Pegol (N9-GP) in Previously Untreated Patients With Haemophilia B
    NCT02141074
    Conditions:   Congenital Bleeding Disorder;   Haemophilia B
    Intervention:   Drug: nonacog beta pegol
    Sponsor:   Novo Nordisk A/S
    Recruiting
  • Phase 3 Alogliptin Pediatric Study
    NCT02856113
    Condition:   Diabetes Mellitus, Type 2
    Interventions:   Drug: Alogliptin Benzoate;   Drug: Placebo
    Sponsor:   Takeda
    Recruiting
  • Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients With Down Syndrome
    NCT02521493
    Conditions:   Acute Myeloid Leukemia;   Down Syndrome;   Myelodysplastic Syndrome;   Myeloid Leukemia Associated With Down Syndrome;   Myeloproliferative Neoplasm
    Interventions:   Drug: Asparaginase;   Drug: Asparaginase Erwinia chrysanthemi;   Drug: Cytarabine;   Drug: Daunorubicin;   Drug: Daunorubicin Hydrochloride;   Drug: Etoposide;   Other: Laboratory Biomarker Analysis;   Drug: Mitoxantrone;   Drug: Mitoxantrone Hydrochloride;   Drug: Thioguanine
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting
  • Apixaban for the Acute Treatment of Venous Thromboembolism in Children
    NCT02464969
    Condition:   Venous Thromboembolism
    Interventions:   Drug: Apixaban;   Drug: Standard of Care
    Sponsors:   Pfizer;   Bristol-Myers Squibb
    Recruiting
  • Safety of and Immune Response to Dolutegravir in HIV-1 Infected Infants, Children, and Adolescents
    NCT01302847
    Condition:   HIV Infections
    Interventions:   Drug: Dolutegravir (DTG) film-coated tablets;   Drug: DTG granules for suspension;   Drug: DTG dispersible tablets
    Sponsor:   National Institute of Allergy and Infectious Diseases (NIAID)
    Recruiting
  • S1602: Different Strains of BCG With or Without Vaccine in High Grade Non- Muscle Invasive Bladder Cancer
    NCT03091660
    Conditions:   Stage 0 Bladder Urothelial Carcinoma;   Stage 0is Bladder Urothelial Carcinoma;   Stage I Bladder Urothelial Carcinoma
    Interventions:   Biological: BCG Solution;   Biological: BCG Tokyo-172 Strain Solution;   Biological: BCG Tokyo-172 Strain Vaccine;   Other: Laboratory Biomarker Analysis
    Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
    Recruiting
  • Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy
    NCT00042289
    Condition:   HIV Infections
    Interventions:   Drug: atazanavir/cobicistat;   Drug: darunavir/ritonavir;   Drug: darunavir/cobicistat;   Drug: etravirine;   Drug: elvitegravir/cobicistat;   Drug: dolutegravir;   Drug: tenofovir alafenamide fumarate (TAF);   Drug: TAF/cobicistat;   Drug: TAF/ritonavir;   Drug: efavirenz;   Drug: lopinavir/ritonavir;   Drug: nevirapine;   Drug: rifampicin;   Drug: ethambutol;   Drug: isoniazid;   Drug: pyrazinamide;   Drug: kanamycin;   Drug: amikacin;   Drug: capreomycin;   Drug: moxifloxacin;   Drug: levofloxacin;   Drug: ofloxacin;   Drug: ethionamide/prothionamide;   Drug: terizidone/cycloserine;   Drug: para-aminosalicylic acid (PAS);   Drug: high dose isoniazid (INH);   Drug: bedaquiline;   Drug: clofazamine;   Drug: delamanid;   Drug: linezolid;   Drug: pretomanid;   Drug: atazanavir/ritonavir/tenofovir;   Drug: ethinyl estradiol oral contraceptive;   Drug: etonogestrel implant
    Sponsors:   National Institute of Allergy and Infectious Diseases (NIAID);   Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
    Recruiting
  • The Global cVAD Study
    NCT04136392
    Condition:   Cardiovascular Diseases
    Intervention:   Device: ABIOMED, Inc. hemodynamic support devices
    Sponsors:   Abiomed Inc.;   Beth Israel Deaconess Medical Center;   Yale University
    Recruiting
  • Rucaparib in Treating Patients With Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)
    NCT03845296
    Conditions:   Deleterious BRCA1 Gene Mutation;   Deleterious BRCA2 Gene Mutation;   Loss of Heterozygosity;   Lung Non-Small Cell Squamous Carcinoma;   Recurrent Large Cell Lung Carcinoma;   Recurrent Lung Adenocarcinoma;   Recurrent Lung Non-Small Cell Carcinoma;   Recurrent Non-Squamous Non-Small Cell Lung Carcinoma;   Stage IV Lung Cancer AJCC v8;   Stage IVA Lung Cancer AJCC v8;   Stage IVB Lung Cancer AJCC v8
    Intervention:   Drug: Rucaparib
    Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
    Recruiting
  • Irinotecan Hydrochloride, Temozolomide, and Dinutuximab With or Without Eflornithine in Treating Patients With Relapsed or Refractory Neuroblastoma
    NCT03794349
    Conditions:   Ganglioneuroblastoma;   Recurrent Neuroblastoma;   Refractory Neuroblastoma
    Interventions:   Biological: Dinutuximab;   Drug: Eflornithine;   Drug: Irinotecan;   Biological: Sargramostim;   Drug: Temozolomide
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting
  • A Multicenter, Randomized, Double-Blind, Placebo Controlled Induction Study to Evaluate the Efficacy and Safety of Risankizumab in Subjects With Moderately to Severely Active Ulcerative Colitis Who Have Failed Prior Biologic Therapy
    NCT03398148
    Condition:   Ulcerative Colitis (UC)
    Interventions:   Drug: risankizumab IV;   Drug: placebo for risankizumab;   Drug: risankizumab SC
    Sponsor:   AbbVie
    Recruiting
  • A Study to Assess the Efficacy and Safety of Risankizumab in Subjects With Ulcerative Colitis Who Responded to Induction Treatment in M16-067 or M16-065
    NCT03398135
    Condition:   Ulcerative Colitis (UC)
    Interventions:   Drug: risankizumab;   Drug: placebo for risankizumab
    Sponsor:   AbbVie
    Recruiting
  • A Study of the Efficacy and Safety of Risankizumab in Subjects With Moderately to Severely Active Crohn's Disease
    NCT03105128
    Condition:   Crohn's Disease
    Interventions:   Drug: placebo for risankizumab;   Drug: risankizumab IV;   Drug: risankizumab SC
    Sponsor:   AbbVie
    Recruiting
  • A Study to Assess the Efficacy and Safety of Risankizumab in Subjects With Moderately to Severely Active Crohn's Disease Who Failed Prior Biologic Treatment
    NCT03104413
    Condition:   Crohn's Disease
    Interventions:   Drug: placebo for risankizumab IV;   Drug: risankizumab SC;   Drug: risankizumab IV
    Sponsor:   AbbVie
    Recruiting
  • Carvedilol in Preventing Heart Failure in Childhood Cancer Survivors
    NCT02717507
    Condition:   Cancer Survivor
    Interventions:   Drug: Carvedilol;   Other: Laboratory Biomarker Analysis;   Other: Pharmacogenomic Study;   Other: Pharmacological Study;   Other: Placebo;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting
  • Chronic Hypertension and Pregnancy (CHAP) Project
    NCT02299414
    Condition:   Hypertension
    Interventions:   Drug: Anti-hypertensive therapy;   Other: No anti-hypertensive therapy (unless BP is severe)
    Sponsors:   University of Alabama at Birmingham;   Columbia University;   Drexel University College of Medicine;   Rutgers, The State University of New Jersey;   Lehigh Valley Hospital;   Saint Peters University Hospital;   Christiana Care Health Services;   Washington University School of Medicine;   Duke University;   University of Texas Southwestern Medical Center;   The University of Texas Health Science Center, Houston;   Stanford University;   University of Pennsylvania;   The University of Texas Medical Branch, Galveston;   University of Utah;   Intermountain Health Care, Inc.;   University of California, San Francisco;   Johns Hopkins University;   University of Pittsburgh;   Ochsner Health System;   University of North Carolina, Chapel Hill;   National Heart, Lung, and Blood Institute (NHLBI);   WakeMed Health and Hospitals;   San Francisco General Hospital;   McKay-Dee Hospital;   Winthrop University Hospital;   New York Hospital Queens;   Latter Day Saints Hospital;   Lyndon B Johnson General Hospital;   Virtua Medical Group;   Bayview Medical Center;   Duke Regional Hospital;   Utah Valley Regional Medical Center;   Northwestern;   Brown (WIHRI);   Baylor College of Medicine;   Case Western/Metro Health;   Ohio State University;   University of Iowa;   University of California, San Diego;   Indiana University;   Unity Point Health-Meriter Hospital WI;   Weill Medical College of Cornell University;   University of Oklahoma;   Medical University of South Carolina;   Beaumont Hospital;   University of Colorado, Denver;   University of Kansas Medical Center;   Denver Health and Hospital Authority;   Gundersen Health System;   Aurora Health Care;   Oregon Health and Science University;   Medical College of Wisconsin;   Temple University;   New Jersey Medical School;   University of South Alabama;   Vanderbilt University;   University of Arkansas;   Miami Valley Hospital;   Emory University;   St. Luke's Hospital and Health Network, Pennsylvania;   Cleveland Clinic Fairview Hospital;   University of Tennessee Health Science Center;   TriHealth Inc.;   Cleveland Clinic Hillcrest Hospital;   Tulane University;   Yale University;   Arrowhead Regional Medical Center;   Geisinger Clinic
    Recruiting
  • OPsumit USers Registry
    NCT02126943
    Condition:   Pulmonary Arterial Hypertension
    Intervention:   Drug: Opsumit (macitentan)
    Sponsor:   Actelion
    Recruiting
  • Study to Evaluate Safety and Efficacy of Dapagliflozin and Saxagliptin in Patients With Type 2 Diabetes Mellitus Aged 10 to Below 18 Years Old
    NCT03199053
    Condition:   Diabetes Mellitus, Type 2
    Interventions:   Drug: Dapagliflozin;   Drug: Saxagliptin;   Drug: Placebo
    Sponsor:   AstraZeneca
    Recruiting
  • Iobenguane I-131 or Crizotinib and Standard Therapy in Treating Younger Patients With Newly-Diagnosed High-Risk Neuroblastoma or Ganglioneuroblastoma
    NCT03126916
    Conditions:   Ganglioneuroblastoma;   INRG Stage L2;   INRG Stage M;   INRG Stage MS;   Neuroblastoma
    Interventions:   Procedure: Autologous Hematopoietic Stem Cell Transplantation;   Drug: Busulfan;   Drug: Carboplatin;   Drug: Cisplatin;   Drug: Crizotinib;   Drug: Cyclophosphamide;   Drug: Dexrazoxane;   Drug: Dexrazoxane Hydrochloride;   Biological: Dinutuximab;   Drug: Doxorubicin;   Drug: Doxorubicin Hydrochloride;   Drug: Etoposide;   Drug: Etoposide Phosphate;   Radiation: External Beam Radiation Therapy;   Radiation: Iobenguane I-131;   Drug: Isotretinoin;   Drug: Melphalan;   Drug: Melphalan Hydrochloride;   Biological: Sargramostim;   Procedure: Therapeutic Conventional Surgery;   Drug: Thiotepa;   Drug: Topotecan;   Drug: Topotecan Hydrochloride;   Drug: Vincristine;   Drug: Vincristine Sulfate
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting
  • Active Surveillance, Bleomycin, Carboplatin, Etoposide, or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors
    NCT03067181
    Conditions:   Childhood Extracranial Germ Cell Tumor;   Extragonadal Embryonal Carcinoma;   Germ Cell Tumor;   Malignant Germ Cell Tumor;   Malignant Ovarian Teratoma;   Stage I Ovarian Choriocarcinoma;   Stage I Ovarian Embryonal Carcinoma AJCC v6 and v7;   Stage I Ovarian Teratoma AJCC v6 and v7;   Stage I Ovarian Yolk Sac Tumor AJCC v6 and v7;   Stage I Testicular Choriocarcinoma AJCC v6 and v7;   Stage I Testicular Embryonal Carcinoma AJCC v6 and v7;   Stage I Testicular Yolk Sac Tumor AJCC v6 and v7;   Stage II Ovarian Choriocarcinoma;   Stage II Ovarian Embryonal Carcinoma AJCC v6 and v7;   Stage II Ovarian Yolk Sac Tumor AJCC v6 and v7;   Stage II Testicular Choriocarcinoma AJCC v6 and v7;   Stage II Testicular Embryonal Carcinoma AJCC v6 and v7;   Stage II Testicular Yolk Sac Tumor AJCC v6 and v7;   Stage III Ovarian Choriocarcinoma;   Stage III Ovarian Embryonal Carcinoma AJCC v6 and v7;   Stage III Ovarian Yolk Sac Tumor AJCC v6 and v7;   Stage III Testicular Choriocarcinoma AJCC v6 and v7;   Stage III Testicular Embryonal Carcinoma AJCC v6 and v7;   Stage III Testicular Yolk Sac Tumor AJCC v6 and v7;   Stage IV Ovarian Choriocarcinoma;   Stage IV Ovarian Embryonal Carcinoma AJCC v6 and v7;   Stage IV Ovarian Yolk Sac Tumor AJCC v6 and v7;   Testicular Mixed Choriocarcinoma and Embryonal Carcinoma;   Testicular Mixed Choriocarcinoma and Teratoma;   Testicular Mixed Choriocarcinoma and Yolk Sac Tumor
    Interventions:   Other: Best Practice;   Drug: Bleomycin;   Biological: Bleomycin Sulfate;   Drug: Carboplatin;   Drug: Cisplatin;   Drug: Etoposide;   Drug: Etoposide Phosphate;   Other: Laboratory Biomarker Analysis;   Other: Pharmacogenomic Study;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting
  • Lactobacillus Plantarum in Preventing Acute Graft Versus Host Disease in Children Undergoing Donor Stem Cell Transplant
    NCT03057054
    Condition:   Malignant Neoplasm
    Interventions:   Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Biological: Lactobacillus plantarum strain 299;   Biological: Lactobacillus plantarum strain 299v;   Other: Placebo
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting
  • Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
    NCT03007147
    Conditions:   B Acute Lymphoblastic Leukemia;   BCR-ABL1 Fusion Protein Expression;   Minimal Residual Disease;   Philadelphia Chromosome Positive;   T Acute Lymphoblastic Leukemia;   Untreated Adult Acute Lymphoblastic Leukemia;   Untreated Childhood Acute Lymphoblastic Leukemia
    Interventions:   Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Drug: Cyclophosphamide;   Drug: Cytarabine;   Drug: Daunorubicin Hydrochloride;   Drug: Dexamethasone;   Drug: Dexrazoxane Hydrochloride;   Drug: Doxorubicin;   Drug: Etoposide;   Biological: Filgrastim;   Drug: Ifosfamide;   Drug: Imatinib Mesylate;   Other: Laboratory Biomarker Analysis;   Drug: Leucovorin Calcium;   Drug: Mercaptopurine;   Drug: Methotrexate;   Drug: Methylprednisolone;   Drug: Pegaspargase;   Drug: Prednisolone;   Other: Questionnaire Administration;   Drug: Therapeutic Hydrocortisone;   Drug: Thioguanine;   Drug: Vincristine Sulfate
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI);   University of Milano Bicocca
    Recruiting
  • Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors
    NCT02867592
    Conditions:   Adrenal Cortex Carcinoma;   Alveolar Soft Part Sarcoma;   Central Nervous System Neoplasm;   Childhood Clear Cell Sarcoma of Soft Parts;   Clear Cell Sarcoma of Soft Tissue;   Ewing Sarcoma;   Hepatoblastoma;   Hepatocellular Carcinoma;   Osteosarcoma;   Recurrent Adrenal Cortex Carcinoma;   Recurrent Alveolar Soft Part Sarcoma;   Recurrent Ewing Sarcoma;   Recurrent Hepatoblastoma;   Recurrent Hepatocellular Carcinoma;   Recurrent Malignant Central Nervous System Neoplasm;   Recurrent Malignant Solid Neoplasm;   Recurrent Osteosarcoma;   Recurrent Renal Cell Carcinoma;   Recurrent Rhabdomyosarcoma;   Recurrent Soft Tissue Sarcoma;   Recurrent Thyroid Gland Medullary Carcinoma;   Refractory Ewing Sarcoma;   Refractory Malignant Central Nervous System Neoplasm;   Refractory Malignant Solid Neoplasm;   Refractory Osteosarcoma;   Refractory Rhabdomyosarcoma;   Refractory Soft Tissue Sarcoma;   Renal Cell Carcinoma;   Rhabdomyosarcoma;   Solid Neoplasm;   Thyroid Gland Medullary Carcinoma;   Wilms Tumor
    Interventions:   Drug: Cabozantinib;   Drug: Cabozantinib S-malate;   Other: Pharmacological Study
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • Neuropsychological and Behavioral Testing in Younger Patients With Cancer
    NCT00772200
    Conditions:   Childhood Malignant Neoplasm;   Cognitive Side Effects of Cancer Therapy
    Interventions:   Procedure: Cognitive Assessment;   Other: Quality-of-Life Assessment
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting
  • Bone Marrow Transplantation vs Standard of Care in Patients With Severe Sickle Cell Disease (BMT CTN 1503)
    NCT02766465
    Condition:   Sickle Cell Disease
    Interventions:   Drug: Busulfan;   Drug: Fludarabine;   Drug: r-ATG;   Procedure: Hematopoietic Cell Transplant;   Drug: Tacrolimus;   Drug: Methotrexate;   Procedure: Standard of Care
    Sponsors:   Medical College of Wisconsin;   National Heart, Lung, and Blood Institute (NHLBI);   Blood and Marrow Transplant Clinical Trials Network;   Dana-Farber Cancer Institute;   National Marrow Donor Program;   Emory University
    Recruiting
  • Campath/Fludarabine/Melphalan Transplant Conditioning for Non-Malignant Diseases
    NCT00920972
    Conditions:   Metabolic Disorders;   Hematologic, Immune, or Bone Marrow Disorders;   Hemoglobinopathies;   Non-malignant Disorders
    Interventions:   Drug: Treatment Plan 1: Stratum 1;   Drug: Treatment Plan 2: Strata 2, 3, or 4;   Drug: GVHD Regimen A: UCB Recipients;   Drug: GVHD Regimen B: BM Recipients
    Sponsors:   Washington University School of Medicine;   St. Louis Children's Hospital
    Recruiting
  • Natural History Study Protocol in PMM2-CDG (CDG-Ia)
    NCT03173300
    Condition:   Phosphomannomutase 2 Deficiency
    Intervention:  
    Sponsor:   Glycomine, Inc.
    Recruiting
  • Phase 3 Study of Oral Ibrexafungerp (SCY-078) Vs. Placebo in Subjects With Recurrent Vulvovaginal Candidiasis (VVC)
    NCT04029116
    Condition:   Recurrent Vulvovaginal Candidiasis
    Interventions:   Drug: Fluconazole Tablet;   Drug: IBREXAFUNGERP;   Drug: Placebo oral tablet
    Sponsor:   Scynexis, Inc.
    Recruiting
  • Non-interventional Post-authorisation Study to Document the Immunogenicity, Safety, and Efficacy of NUWIQ
    NCT02962765
    Condition:   Hemophilia A
    Intervention:  
    Sponsor:   Octapharma
    Recruiting
  • Zoliflodacin in Uncomplicated Gonorrhoea
    NCT03959527
    Condition:   Gonorrhea
    Interventions:   Drug: zoliflodacin;   Drug: ceftriaxone;   Drug: azithromycin
    Sponsor:   Global Antibiotics Research and Development Partnership
    Recruiting
  • Intravenous Ganaxolone as Adjunctive Therapy to Treat Subjects With Status Epilepticus
    NCT03350035
    Conditions:   Status Epilepticus;   Convulsive Status EPILEPTICUS;   Non Convulsive Status Epilepticus;   Epilepsy
    Interventions:   Drug: Ganaxolone;   Drug: Placebo
    Sponsor:   Marinus Pharmaceuticals
    Recruiting
  • NeuMoDx PrEDiCTiNG Study Evaluation Plan
    NCT03970850
    Conditions:   Chlamydia Trachomatis Infection;   Neisseria Gonorrheae Infection
    Interventions:   Diagnostic Test: NeuMoDx CT/NG Assay;   Diagnostic Test: FDA-cleared NAATs
    Sponsors:   NeuMoDx Molecular, Inc.;   NAMSA
    Recruiting
  • Evaluating Effectiveness and Long Term Safety of Damoctocog Alfa Pegol in Patients, Who Have Been Diagnosed With Hemophilia A
    NCT03932201
    Condition:   Hemophilia A
    Intervention:   Drug: Damoctocog alfa pegol (Jivi, Bay94-9027)
    Sponsor:   Bayer
    Recruiting
  • Pulmonary Hypertension Association Registry
    NCT04071327
    Conditions:   Pulmonary Arterial Hypertension;   Chronic Thromboembolic Pulmonary Hypertension;   Pulmonary Hypertension
    Intervention:  
    Sponsors:   Pulmonary Hypertension Association, Inc.;   University of Washington, the Collaborative Health Studies Coordinating Center
    Recruiting
  • Study of the Safety, Tolerability and Efficacy of BTX 1204 in Patients With Moderate Atopic Dermatitis
    NCT03824405
    Condition:   Atopic Dermatitis
    Interventions:   Drug: BTX 1204;   Drug: Vehicle
    Sponsor:   Botanix Pharmaceuticals
    Recruiting
  • A Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Moderately to Severely Active Ulcerative Colitis
    NCT03653026
    Condition:   Ulcerative Colitis (UC)
    Interventions:   Drug: Upadacitinib (ABT-494);   Drug: Placebo
    Sponsor:   AbbVie
    Recruiting
  • Study to Investigate Efficacy and Safety of PF-04965842 in Subjects Aged 12 Years and Over With Moderate to Severe Atopic Dermatitis With the Option of Rescue Treatment in Flaring Subjects
    NCT03627767
    Conditions:   Dermatitis;   Dermatitis, Atopic;   Eczema;   Skin Diseases;   Skin Diseases, Genetic;   Genetic Diseases, Inborn;   Skin Diseases, Eczematous;   Hypersensitivity;   Hypersensitivity, Immediate;   Immune System Diseases
    Interventions:   Drug: PF-04965842 100 mg;   Drug: PF-04965842 200 mg;   Drug: Placebo
    Sponsor:   Pfizer
    Recruiting
  • Efficacy and Safety Study of SHP647 as Maintenance Treatment in Participants With Moderate to Severe Crohn's Disease (CARMEN CD 307)
    NCT03627091
    Condition:   Crohn's Disease
    Interventions:   Drug: SHP647;   Other: Placebo
    Sponsor:   Shire
    Recruiting
  • Assessing Physician and Hemophilia A Patient Reasons and Expectations for Switching Treatment to Kovaltry: A Nested Study Within an Existing Registry
    NCT03603275
    Condition:   Hemophilia A
    Intervention:   Drug: Antihemophilic Factor (Kovaltry, BAY81-8973)
    Sponsors:   Bayer;   American Thrombosis and Hemostasis Network
    Recruiting
  • Disrupt CAD III With the Shockwave Coronary IVL System
    NCT03595176
    Conditions:   Coronary Artery Disease;   Myocardial Infarction
    Intervention:   Device: Lithotripsy
    Sponsor:   Shockwave Medical, Inc.
    Recruiting
  • Axitinib and Nivolumab in Treating Patients With Unresectable or Metastatic TFE/Translocation Renal Cell Carcinoma
    NCT03595124
    Conditions:   Metastatic Renal Cell Carcinoma;   Renal Cell Carcinoma Associated With Xp11.2 Translocations/TFE3 Gene Fusions;   Stage III Renal Cell Cancer AJCC v8;   Stage IV Renal Cell Cancer AJCC v8;   Unresectable Renal Cell Carcinoma
    Interventions:   Drug: Axitinib;   Biological: Nivolumab
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • A Study to Test the Safety of the Investigational Drug Loxo-195 in Children and Adults That May Treat Cancer
    NCT03215511
    Condition:   Solid Tumors Harboring NTRK Fusion
    Intervention:   Drug: BAY2731954
    Sponsor:   Bayer
    Recruiting
  • Efficacy and Safety Study of SHP647 as Induction Therapy in Participants With Moderate to Severe Crohn's Disease (CARMEN CD 306)
    NCT03566823
    Condition:   Crohn's Disease
    Interventions:   Biological: SHP647;   Other: Placebo
    Sponsor:   Shire
    Recruiting
  • Registry of Subjects With Drug Resistant Epilepsy and Treated With the VNS Therapy System.
    NCT03529045
    Conditions:   Epilepsy;   Seizures;   Drug Resistant Epilepsy
    Intervention:   Device: Vagus Nerve Stimulation (VNS) Therapy
    Sponsor:   LivaNova
    Recruiting
  • Study of Sparsentan in Patients With Primary Focal Segmental Glomerulosclerosis (FSGS)
    NCT03493685
    Condition:   Focal Segmental Glomerulosclerosis
    Interventions:   Drug: sparsentan;   Drug: irbesartan
    Sponsor:   Retrophin, Inc.
    Recruiting
  • An Extension Study of Oral Ozanimod for Moderately to Severely Active Crohn's Disease
    NCT03467958
    Condition:   Crohn Disease
    Intervention:   Drug: Ozanimod
    Sponsor:   Celgene
    Recruiting
  • A Placebo-Controlled Study of Oral Ozanimod as Maintenance Therapy for Moderately to Severely Active Crohn's Disease
    NCT03464097
    Condition:   Crohn Disease
    Interventions:   Drug: Ozanimod;   Other: Placebo
    Sponsor:   Celgene
    Recruiting
  • Induction Study #1 of Oral Ozanimod as Induction Therapy for Moderately to Severely Active Crohn's Disease
    NCT03440372
    Condition:   Crohn Disease
    Interventions:   Drug: Ozanimod;   Other: Placebo
    Sponsor:   Celgene
    Recruiting
  • Study to Evaluate Efficacy and Safety of PF-04965842 With or Without Topical Medications in Subjects Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis
    NCT03422822
    Condition:   Dermatitis, Atopic
    Interventions:   Drug: PF-04965842 100 mg;   Drug: PF-04965842 200 mg;   Drug: Placebo
    Sponsor:   Pfizer
    Recruiting
  • A Study to Evaluate the Efficacy and Safety of Pimodivir in Combination With the Standard-of-Care Treatment in Adolescent, Adult, and Elderly Non-Hospitalized Participants With Influenza A Infection Who Are at Risk of Developing Complications
    NCT03381196
    Condition:   Influenza A
    Interventions:   Drug: Pimodivir 600 mg;   Drug: Placebo;   Other: SOC Treatment
    Sponsor:   Janssen Research & Development, LLC
    Recruiting
  • An Open-Label Study of Defibrotide for the Prevention of Acute Graft-versus-Host-Disease (AGvHD)
    NCT03339297
    Conditions:   Graft-versus-host Disease;   Acute-graft-versus-host Disease
    Interventions:   Drug: Defibrotide;   Drug: Standard of Care
    Sponsor:   Jazz Pharmaceuticals
    Recruiting
  • Fecal Microbiota Transplant National Registry
    NCT03325855
    Conditions:   Fecal Microbiota Transplantation;   Clostridium Difficile Infection;   Gut Microbiome
    Intervention:   Other: None - Observational
    Sponsors:   American Gastroenterological Association;   OpenBiome;   University of California, San Diego;   Icahn School of Medicine at Mount Sinai
    Recruiting
  • Observational Study to Evaluate, Under Real-world Practice Conditions, the Safety and Effectiveness of Regorafenib in Patients Diagnosed With Unresectable Hepatocellular Carcinoma (uHCC)
    NCT03289273
    Condition:   Liver Neoplasms
    Intervention:   Drug: Regorafenib (Stivarga, BAY73-4506)
    Sponsor:   Bayer
    Recruiting
  • A Safety Extension Study of SHP647 in Participants With Moderate to Severe Ulcerative Colitis or Crohn's Disease (AIDA)
    NCT03283085
    Conditions:   Crohn's Disease;   Ulcerative Colitis
    Interventions:   Drug: 25 mg SHP647;   Drug: 75 mg SHP647
    Sponsor:   Shire
    Recruiting
  • Phase 1/2 Study of LOXO-292 in Patients With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer
    NCT03157128
    Conditions:   Non-Small Cell Lung Cancer;   Medullary Thyroid Cancer;   Colon Cancer;   Any Solid Tumor
    Intervention:   Drug: LOXO-292
    Sponsor:   Loxo Oncology, Inc.
    Recruiting
  • DCM Precision Medicine Study
    NCT03037632
    Condition:   Idiopathic Dilated Cardiomyopathy
    Intervention:   Behavioral: Family Heart Talk Booklet
    Sponsors:   Ray Hershberger;   National Heart, Lung, and Blood Institute (NHLBI);   National Human Genome Research Institute (NHGRI)
    Recruiting
  • Efficacy and Safety Study of Maribavir Treatment Compared to Investigator-assigned Treatment in Transplant Recipients With Cytomegalovirus (CMV) Infections That Are Refractory or Resistant to Treatment With Ganciclovir, Valganciclovir, Foscarnet, or Cidofovir
    NCT02931539
    Condition:   Cytomegalovirus (CMV)
    Interventions:   Drug: Maribavir;   Drug: Ganciclovir;   Drug: Valganciclovir;   Drug: Foscarnet;   Drug: Cidofovir
    Sponsor:   Shire
    Recruiting
  • Study of Perampanel as Adjunctive Treatment for Inadequately Controlled Seizures Associated With Lennox-Gastaut Syndrome
    NCT02834793
    Condition:   Lennox-Gastaut Syndrome (LGS)
    Interventions:   Drug: Placebo;   Drug: Perampanel
    Sponsor:   Eisai Inc.
    Recruiting
  • A Study to Evaluate the Safety and Efficacy of Upadacitinib (ABT-494) for Induction and Maintenance Therapy in Subjects With Moderately to Severely Active Ulcerative Colitis (UC)
    NCT02819635
    Condition:   Ulcerative Colitis (UC)
    Interventions:   Drug: Placebo;   Drug: Updacitinib (ABT-494)
    Sponsor:   AbbVie
    Recruiting
  • A 5-year Longitudinal Observational Study of Patients With Nonalcoholic Fatty Liver (NAFL) or Nonalcoholic Steatohepatitis (NASH)
    NCT02815891
    Conditions:   Nonalcoholic Fatty Liver;   Nonalcoholic Steatohepatitis
    Intervention:  
    Sponsor:   Target PharmaSolutions, Inc.
    Recruiting
  • An Study of Patients With Ph- Chromosome-negative Relapsed or Refractory Acute Lymphoblastic Leukemia in the US
    NCT02783651
    Condition:   Relapsed/Refractory Acute Lymphoblastic Leukemia
    Intervention:   Other: Other
    Sponsor:   Amgen
    Recruiting
  • A Trial Comparing Cardiovascular Safety of Degarelix Versus Leuprolide in Patients With Advanced Prostate Cancer and Cardiovascular Disease
    NCT02663908
    Condition:   Prostate Cancer
    Interventions:   Drug: Degarelix;   Drug: Leuprolide
    Sponsors:   Ferring Pharmaceuticals;   Memorial Sloan Kettering Cancer Center;   Duke Clinical Research Institute
    Recruiting
  • ATHN 2: Factor Switching Study
    NCT02546622
    Condition:   Hemophilia
    Interventions:   Biological: Factor VIII Replacement Products for Hemophilia which were FDA approved after January 1, 2013;   Biological: Factor IX Replacement Products for Hemophilia which were FDA approved after January 1, 2013
    Sponsors:   American Thrombosis and Hemostasis Network;   Shire;   CSL Behring;   Bioverativ Therapeutics Inc.;   Bayer
    Recruiting
  • Standard-Dose Combination Chemotherapy or High-Dose Combination Chemotherapy and Stem Cell Transplant in Treating Patients With Relapsed or Refractory Germ Cell Tumors
    NCT02375204
    Conditions:   Germ Cell Tumor;   Teratoma;   Choriocarcinoma;   Germinoma;   Mixed Germ Cell Tumor;   Yolk Sac Tumor;   Childhood Teratoma;   Malignant Germ Cell Neoplasm;   Extragonadal Seminoma;   Non-seminomatous Germ Cell Tumor;   Seminoma
    Interventions:   Drug: paclitaxel;   Drug: ifosfamide;   Drug: cisplatin;   Drug: pegylated G-CSF;   Drug: G-CSF;   Drug: carboplatin;   Drug: etoposide phosphate;   Procedure: stem cell reinfusion
    Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI);   European Organisation for Research and Treatment of Cancer - EORTC;   Movember Foundation;   Institute of Cancer Research (ICR), United Kingdom;   Cancer Research UK;   UNICANCER;   Irish Group CTI
    Recruiting
  • Registry for Participants With Short Bowel Syndrome
    NCT01990040
    Condition:   Short Bowel Syndrome
    Intervention:  
    Sponsor:   Shire
    Recruiting
  • Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment
    NCT01790152
    Conditions:   Hodgkin Lymphoma in Remission;   Leukemia in Remission;   Lymphoblastic Lymphoma;   Osteosarcoma;   Recurrent Leukemia;   Recurrent Lymphoma;   Recurrent Malignant Neoplasm
    Interventions:   Other: Assessment of Therapy Complications;   Other: Laboratory Biomarker Analysis;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting
  • Product Surveillance Registry
    NCT01524276
    Conditions:   Cardiac Rhythm Disorders;   Urological Disorders;   Neurological Disorders;   Cardiovascular Disorders;   Digestive Disorders;   Intracranial Aneurysm;   Mechanical Circulatory Support
    Intervention:  
    Sponsor:   Medtronic
    Recruiting
  • Surveillance Monitoring for ART Toxicities Study in HIV Uninfected Children Born to HIV Infected Women
    NCT01310023
    Condition:   Antiretroviral Toxicity
    Intervention:  
    Sponsors:   Harvard School of Public Health;   Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD);   National Institute on Drug Abuse (NIDA);   National Institute of Allergy and Infectious Diseases (NIAID);   National Institute of Mental Health (NIMH);   National Heart, Lung, and Blood Institute (NHLBI);   National Institute on Deafness and Other Communication Disorders (NIDCD);   National Institute on Alcohol Abuse and Alcoholism (NIAAA);   National Institute of Neurological Disorders and Stroke (NINDS);   Tulane University School of Medicine;   National Institute of Dental and Craniofacial Research (NIDCR);   NIH Office of AIDS Research (OAR)
    Recruiting
  • Natural History Study of SCID Disorders
    NCT01186913
    Conditions:   Severe Combined Immunodeficiency (SCID);   Leaky SCID;   Omenn Syndrome;   Reticular Dysgenesis;   ADA SCID;   XSCID
    Intervention:  
    Sponsors:   National Institute of Allergy and Infectious Diseases (NIAID);   Primary Immune Deficiency Treatment Consortium (PIDTC);   Office of Rare Diseases (ORD);   National Center for Advancing Translational Science (NCATS)
    Recruiting
  • Product Performance Report: Evaluate Long-term Reliability & Performance of Medtronic Marketed Cardiac Therapy Products
    NCT00271180
    Conditions:   Arrhythmia;   Bradycardia;   Heart Failure;   Sinus Tachycardia
    Intervention:   Device: Device
    Sponsor:   Medtronic
    Recruiting

Popular Now

  • Privacy Policy
  • Ad and Cookie Policy
  • Infringement Policy
  • Terms of Use
  • Email Policy
  • Contact Us
  • Post Clinical Trials
  • Join Clinical Trials
  • Volunteer Login
  • Recruiters Login
  • Frequently Asked Questions
  • Blog
  • Find Clinical Trials
  • Find Volunteers
  • Trials by Category
  • Trials by Location
  • Volunteers by Category
  • Volunteers by Location
All clinical trials are registered and certified with clinicaltrials.gov. Data via U.S. National Library of Medicine,U.S. National Institutes of Health, U.S. Department of Health & Human Services. JoinClinicaltrials.com (Aunica Media llc) is a free resource that provides individuals and companies with information regarding clinical trials that are being conducted nationwide. Aunica Media llc does not conduct clinical trials nor endorses them. Please consult your doctor or physician before participating. And Ye shall know the truth, and the truth shall make you free
©2001-2019 Aunica Media LLC